Everyone is looking to attract new companies. And Antares (AMEX:AIS) is looking for a new home. The drug developer and medical device business has “maxed out” its office space in Ewing, N.J. But good luck getting the company to move its headquarters far. Paul Wotton, Antares’ CEO said he is keen to keep the company […]
The power of suggestion and anticipation can be just as potent as a drug it seems, especially when it comes to sex. Or at least that’s one of the conclusions that could be reached in the aftermath of phase 3 clinical trials testing the efficacy of LibiGel, which is designed to treat sexual dysfunction in […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A gel developed by Antares (AMEX:AIS) and licensed to BioSante Pharmaceuticals (NASDAQ:BPAX) to treat female sexual dysfunction failed two phase 3 clinical trials testing efficacy, according to a statement from BioSante. Initial analysis of the data from the trials showed that the tests “did not meet the co-primary or secondary endpoints,” the statement said. LibiGel […]
Antares Pharma (AMEX:AIS) broke through last week with FDA approval of a topical gel to treat overactive bladder. It’s a cash win for the New Jersey company, which will receive royalties from sales and milestone payments for delivery of the drug — called Anturol — to Watson Pharmaceuticals (NYSE:WPI), which will commercialize the product next […]